Home World News Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously... World News Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC By Ogkologos - April 30, 2026 222 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR An Abnormal Baseline Geriatric 8 Screening Tool Score Strongly Associates with... June 26, 2023 ESMO Gynaecological Cancers Congress 2023 February 10, 2023 First Mature Estimation of Median OS for Selpercatinib in Patients with... March 12, 2025 Adjusting to the Challenges of Life After Cancer: An Expert Perspective May 5, 2022 Load more HOT NEWS Mom Gives ‘Elf On The Shelf’ A Wheelchair For Daughter With... What to Know About Navigating Your Cancer Care During An Extreme... FDA Approves Asciminib for Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In...
